Phase 3 trial starts for ulcerative colitis immunotherapy

InDex Pharmaceuticals AB, a privately-held Swedish immunotherapy company, is starting a Phase 3 trial of Kappaproct, which has performed well in earlier tests in treating steroid-resistant ulcerative colitis patients.